This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other specified disorders of amino-acid metabolism / Gamma-glutamyl cycle disorders / Beta-aminoaciduria기타아미노산대사장애 / 감마글루타밀회로의 장애 / 베타아미노산대사장애

Contents and key points
ItemDetails
A. Classification codesICD-10: E72.8 (other specified disorders of amino-acid metabolism) | Special Copayment Reduction: V117 (rare disease)
B. Synonyms5-oxoprolinuria (pyroglutamic aciduria), glutathione synthetase deficiency (GSS), gamma-glutamylcysteine synthetase deficiency (GGCS deficiency), β-alaninemia, beta-aminoisobutyric aciduria, dihydropyrimidinase deficiency (DPYS deficiency)
C. Adult onsetPossibility of adult onset yes — the mild form of glutathione synthetase deficiency is first diagnosed in adulthood as hemolytic anemia, and beta-aminoisobutyric aciduria is mostly asymptomatic and found incidentally on adult urine testing. DPYS deficiency is first recognized as a fluorouracil toxicity crisis during adult chemotherapy.
1. History1970 first description of 5-oxoprolinuria by Jellum → 1974 Meister confirmed GSS deficiency → 1990s cloning of the GGCS and GSS genes → 2001 identification of the DPYS gene.
2. Causes① GSS deficiency (20q11.22): defect in the last step of glutathione synthesis → 5-oxoproline accumulation. ② GGCS deficiency: defect in the first step of glutathione synthesis. ③ DPYS deficiency (8q22.3): defect in pyrimidine degradation → beta-amino acid excretion. ④ Abnormalities of beta-amino acid metabolism.
3. GeneticsGSS: 20q11.22, autosomal recessive. GGCS: 6p12.1. DPYS: 8q22.3, autosomal recessive. Beta-aminoisobutyric aciduria: multiple genes, many normal variants.
4. General epidemiologyGSS deficiency: ~100 cases reported. GGCS deficiency: ultra-rare (~30 cases). DPYS deficiency: ~150 cases. Beta-aminoisobutyric aciduria: carriers in 5~10% of the population, a harmless normal variant.
5. PathophysiologyGSS deficiency: decreased glutathione → disinhibition of γ-GCS → excess γ-glutamylcysteine → accumulation of 5-oxoproline (pyroglutamic acid) → metabolic acidosis and hemolysis. DPYS: blocked degradation of uracil/thymine → accumulation of beta-alanine and beta-aminoisobutyric acid → increased fluorouracil toxicity.
6. SymptomsSevere GSS deficiency: neonatal hemolytic anemia, metabolic acidosis, 5-oxoprolinuria, neurodevelopmental disorder. Mild: hemolytic anemia only. DPYS: asymptomatic (majority) → acute toxicity with fluorouracil administration (mucositis, neurotoxicity).
7. SignsSevere GSS: excessive urinary excretion of 5-oxoproline (pyroglutamic acid), metabolic acidosis, hemolytic anemia (Coombs-negative). DPYS: elevated urinary uracil, thymine and beta-alanine. Decreased blood DPYD activity (risk of fluorouracil toxicity).
8. ScreeningGSS deficiency: urine organic acids (5-oxoproline) in neonatal hemolytic anemia + metabolic acidosis. DPYS: DPYD activity or DPYS gene testing before fluorouracil administration (pharmacogenomic screening).
9. DiagnosisUrine organic acid GC-MS (5-oxoproline, beta-amino acids), plasma glutathione measurement, molecular genetic testing (GSS/GGCS/DPYS NGS), RBC glutathione synthetase activity, DPYD enzyme activity.
10. TreatmentGSS deficiency: vitamins C and E (suppression of oxidative stress), folic acid, transfusion (acute phase of hemolytic anemia). DPYS deficiency: fluorouracil contraindicated or dose markedly reduced. Beta-amino aciduria: no treatment needed.
11. PrognosisSevere GSS: neurodevelopmental disorder, risk of recurrent infections. Mild: normal life possible with control of anemia. DPYS: normal prognosis if fluorouracil is avoided. Beta-amino aciduria: normal prognosis.
12. PreventionGenetic counseling, prenatal diagnosis. GSS deficiency: avoid drugs that induce oxidative stress, antioxidant supplementation. DPYS: pharmacogenomic screening test before cancer treatment (prevention of fluorouracil toxicity).
13. ReferencesRistoff E, Larsson A 2007; Njalsson R et al. 2005; van Kuilenburg AB et al. 2003 and 7 other references.

1. History

The disease group in this chapter includes abnormalities of two metabolic pathways: disorders of the γ-glutamyl cycle and abnormalities of beta-amino acid metabolism. The γ-glutamyl cycle is a mitochondrial-cytosolic pathway responsible for the synthesis and degradation of glutathione, and deficiencies of several enzymes cause diverse phenotypes such as 5-oxoprolinuria, hemolytic anemia and neurological damage.

5-oxoprolinuria (pyroglutamic aciduria) became known in 1970 when the Norwegian researcher Jellum and colleagues first reported excessive excretion of 5-oxoproline (pyroglutamic acid) in the urine of a patient with neurodevelopmental disorder and metabolic acidosis. In 1974, the American metabolism researcher Alton Meister established that glutathione synthetase (GSS) deficiency is the cause of this disease. The feedback inhibition mechanism was elucidated: when glutathione synthesis is blocked, γ-glutamylcysteine synthetase (γ-GCS) is disinhibited and γ-glutamylcysteine is overproduced, which accumulates as 5-oxoproline (pyrrolidone carboxylic acid). In the 1990s, cloning of the GSS gene (20q11.22) was completed, making molecular diagnosis possible.

Gamma-glutamylcysteine synthetase (GGCS, now renamed GCL — glutamate-cysteine ligase) deficiency is much rarer than GSS deficiency and shows a different clinical phenotype of hemolytic anemia and neuromuscular abnormalities.

Unlike dihydropyrimidine dehydrogenase (DPD), dihydropyrimidinase (DPYS) deficiency is a deficiency of the enzyme responsible for the second step of the pyrimidine degradation pathway. In 2001, van Kuilenburg and colleagues characterized the DPYS gene (8q22.3), and excessive urinary excretion of uracil, thymine, beta-alanine and beta-aminoisobutyric acid was confirmed in patients with DPYS deficiency. DPYS deficiency itself is mostly asymptomatic, but its association with toxicity of the anticancer drug 5-fluorouracil (5-FU) is clinically important. Beta-aminoisobutyric aciduria is a benign polymorphic variant observed in 5~10% of the normal population and in most cases is not a clinical disease.


2. Causes

γ-glutamyl cycle disorders result from deficiencies of enzymes involved in glutathione metabolism. Glutathione (γ-Glu-Cys-Gly) is the major intracellular antioxidant and a substrate for various detoxification reactions. Glutathione synthesis takes place in two steps. First, gamma-glutamylcysteine synthetase (GCL, a GCLC/GCLM heterodimer) joins glutamate and cysteine to produce γ-glutamylcysteine. Second, glutathione synthetase (GSS) joins γ-glutamylcysteine and glycine to synthesize glutathione.

GSS deficiency (gene: GSS, 20q11.22): Loss of GSS enzyme function blocks glutathione synthesis. Decreased glutathione → release of GCL feedback inhibition → excess synthesis of γ-glutamylcysteine → accumulation of 5-oxoproline at levels that 5-oxoprolinase (5-OPase) cannot process → 5-oxoprolinuria and metabolic acidosis develop. Decreased glutathione impairs the ability of red blood cells to protect against oxidative damage, causing hemolytic anemia.

GCLC/GCLM deficiency (GGCS deficiency): Deficiency of the catalytic subunit (GCLC, 6p12.1) or modifier subunit (GCLM, 1p22.1) of the GCL complex blocks the first step of glutathione synthesis. Unlike GSS deficiency, there is no 5-oxoproline accumulation, and hemolytic anemia and neuromuscular abnormalities are the main clinical phenotype.

DPYS deficiency (gene: DPYS, 8q22.3): A deficiency of the dihydropyrimidinase enzyme, which converts dihydrouracil and dihydrothymine into beta-ureidopropionic acid and beta-ureidoisobutyric acid in the pyrimidine degradation pathway. In DPYS deficiency, uracil and thymine, dihydrouracil and dihydrothymine, and beta-alanine and beta-aminoisobutyric acid are excreted in the urine. Because 5-fluorouracil (5-FU) is a structural analog of DPYS substrates, an association with increased 5-FU toxicity in patients with DPYS deficiency has been reported, but the clinical impact is less clear than that of DPD (dihydropyrimidine dehydrogenase) deficiency.


3. Genetics

The GSS gene is located on the long arm of chromosome 20 (20q11.22) and consists of 13 exons. The encoded glutathione synthetase is a homodimer enzyme of 474 amino acids. More than 50 pathogenic variants have been reported to date, evenly distributed among missense, nonsense, splicing and small deletion variants. The severe phenotype (with central nervous system abnormalities) is expressed when enzyme activity is below 5%, and the mild phenotype (hemolytic anemia only) with variants that preserve some residual activity. The mode of inheritance is autosomal recessive.

The GCLC gene is located on the short arm of chromosome 6 (6p12.1) and has 19 exons. The GCLM gene is located on the short arm of chromosome 1 (1p22.1). GCLC deficiency shows a more severe phenotype, while GCLM deficiency causes a mild decrease in glutathione. The DPYS gene is located on the long arm of chromosome 8 (8q22.3) and has 10 exons. Dihydropyrimidinase (DPYS) is the second enzyme of pyrimidine degradation, an amidohydrolase with dihydrouracil and dihydrothymine as substrates. The mode of inheritance is autosomal recessive.

Beta-aminoisobutyric aciduria arises from a combination of multiple genetic and environmental factors and is closer to a polygenic trait than to a specific single-gene deficiency. This finding is a normal variant observed in 5~10% of the world population and is not classified as a clinical disease.


4. General epidemiology

GSS deficiency is a rare disease with more than about 100 cases reported in the literature worldwide. Its incidence is estimated at 1 in several hundred thousand to several million births. A relatively large number of cases have been reported in Sweden, which is understood to be due to a founder effect in Scandinavia and systematic diagnostic systems. It is divided into two phenotypes, mild (hemolytic anemia only) and severe (5-oxoprolinuria + neurological abnormalities + hemolytic anemia), and the mild form is more common.

GGCS (GCL) deficiency is ultra-rare, with 30 or fewer cases reported worldwide. There is no sex difference. More than about 150 cases of DPYS deficiency have been reported, found in the form of beta-alaninuria on newborn screening or organic acid testing. DPYS deficiency itself is mostly asymptomatic, but interest in cancer treatment practice is increasing because of the clinical association with increased toxicity in patients receiving 5-fluorouracil chemotherapy.

Beta-aminoisobutyric aciduria is a benign polymorphism observed in 5~10% of the total population, with particularly high frequency in East Asians (about 10~20% in Korean, Japanese and Chinese populations). It is a metabolic trait with no clinical significance.


5. Pathophysiology

Pathophysiology of GSS deficiency: Blocked glutathione synthesis → decreased intracellular glutathione → reduced ability to protect against oxidative stress. At the same time, decreased glutathione releases the feedback inhibition of the GCL enzyme, so GCL activity increases abnormally and γ-glutamylcysteine is synthesized in excess. Excess γ-glutamylcysteine cyclizes spontaneously or is converted to 5-oxoproline (pyroglutamic acid) by the reverse reaction of γ-glutamyltranspeptidase (GGT). The capacity of 5-oxoprolinase (5-OPase, an ATP-dependent enzyme) to convert 5-oxoproline to glutamate is exceeded, and 5-oxoproline accumulates in blood and urine. Massive excretion of 5-oxoproline causes high anion gap metabolic acidosis. In red blood cells, decreased glutathione leads to membrane damage by hydrogen peroxide and reactive oxygen species (ROS), causing Coombs-negative hemolytic anemia. In the severe form, increased oxidative stress in the brain and nervous system is explained as the mechanism of neurodevelopmental disorder.

Pathophysiology of DPYS deficiency: In the pyrimidine degradation pathway, hydrolysis of the ring amide bond of dihydrouracil (DHU) and dihydrothymine (DHT) is blocked. As a result, uracil, thymine, DHU, DHT, β-alanine and β-aminoisobutyric acid accumulate in blood and urine. There is a theoretical possibility of neurotoxicity because β-alanine has a structure similar to the neurotransmitter GABA and can bind GABA receptors, but most patients with DPYS deficiency are asymptomatic. 5-fluorouracil (5-FU) generates dihydrofluorouracil (DHFU), a substrate of DPYS, and in DPYS deficiency the degradation of DHFU and 5-FU is delayed, increasing cytotoxicity. However, DPD deficiency is the more major cause of 5-FU toxicity.


6. Symptoms

Symptoms of GSS deficiency: Divided into two clinical forms by severity. Mild form: hemolytic anemia is the main symptom, and 5-oxoprolinuria is absent or mild. Neonatal jaundice, recurrent hemolytic episodes and anemia persist, and differentiation from iron deficiency anemia or spherocytosis is needed. There are no neurological abnormalities. Severe form: accompanied by 5-oxoprolinuria (pyroglutamic aciduria) and high anion gap metabolic acidosis. Jaundice, anemia, acidosis, vomiting and lethargy appear in the neonatal period. Along with recurrent episodes of acidosis, neurodevelopmental disorder (intellectual disability, developmental delay, seizures) develops in childhood to adolescence. Because patients are sensitive to oxidative stress, infection, surgery and certain drugs (acetaminophen, penicillin, etc.) can worsen acidosis and hemolysis. Cerebellar dysfunction (ataxia) has also rarely been reported.

Symptoms of GGCS deficiency: Hemolytic anemia and neuromuscular abnormalities (seizures, peripheral neuropathy, muscle weakness) are the main symptoms. 5-oxoprolinuria is less prominent than in GSS deficiency.

Symptoms of DPYS deficiency: Mostly asymptomatic. It is found incidentally on urine organic acid testing in the neonatal period, or first recognized when unexpected severe toxicity (severe stomatitis, diarrhea, bone marrow suppression, neurotoxicity) appears during 5-fluorouracil chemotherapy. Intellectual disability and seizures have been reported in some pediatric patients, but it is unclear whether DPYS deficiency is an independent cause.


7. Signs

Laboratory findings:

Neurological signs: Developmental delay, hypotonia and cerebellar ataxia are observed in the severe form of GSS deficiency. EEG shows epileptiform discharges or slow-wave abnormalities. Brain MRI shows mild to moderate atrophy or white matter abnormalities.

Drug-response signs (DPYS deficiency): After administration of 5-fluorouracil-based chemotherapy (5-FU, capecitabine, tegafur), life-threatening toxicity (WHO grade 3~4 mucositis, pancytopenia, neurotoxicity) appears in the first treatment cycle.


8. Screening

GSS deficiency: It is difficult to screen specifically for GSS deficiency by blood amino acids on newborn screening. Clinical suspicion arises from the combination of unexplained metabolic acidosis and hemolytic anemia in the neonatal period. In this case, urine organic acid GC-MS is performed immediately to confirm excessive 5-oxoproline excretion. When 5-oxoproline is detected as the cause of acidosis, GSS deficiency should be suspected first.

However, because 5-oxoproline can also be secondarily elevated with acetaminophen overdose, antibiotic administration (especially flucloxacillin), sepsis, pregnancy and other conditions, the drug and clinical context should be evaluated together.

DPYS deficiency: Pharmacogenomics screening is recommended before chemotherapy. The European pharmacogenomics consortium (CPIC) and the European Society of Clinical Pharmacology (DPWG) recommend performing DPYD (dihydropyrimidine dehydrogenase) genotyping first before 5-FU-based chemotherapy. DPYS deficiency involves a different pathway from DPD deficiency, but urine pyrimidine analysis (elevated uracil/thymine/beta-amino acids) can be a screening method for detecting DPYS deficiency. Elevated beta-alanine and beta-aminoisobutyric acid on neonatal urine organic acid testing lead to the detection of DPYS deficiency.


9. Diagnosis

Confirmation of GSS deficiency: ① Marked elevation of 5-oxoproline (pyroglutamic acid) on urine GC-MS — the primary biochemical marker for diagnosis. ② Plasma/RBC glutathione measurement — markedly decreased GSH. ③ Measurement of GSS enzyme activity in RBCs or leukocytes. ④ NGS analysis of the GSS gene — the standard for confirmation. A history of acetaminophen or flucloxacillin use must be checked to exclude secondary 5-oxoprolinuria.

Confirmation of GGCS deficiency: Decreased RBC GSH + decreased GCL enzyme activity (leukocytes or fibroblasts). NGS analysis of the GCLC/GCLM genes.

Confirmation of DPYS deficiency: ① Urine organic acids (GC-MS or HPLC): elevated uracil, thymine, dihydrouracil, dihydrothymine, β-alanine and β-aminoisobutyric acid. ② DPYS enzyme activity (leukocytes). ③ NGS analysis of the DPYS gene — confirmation. ④ In the context of chemotherapy, DPYD genotyping is also performed in parallel.


10. Treatment

Treatment of GSS deficiency: There is no curative treatment, and suppression of oxidative stress and correction of metabolic acidosis are key. ① Vitamin C (ascorbic acid): high-dose (100~200 mg/kg/day) oral administration reduces oxidative stress and partly compensates for glutathione deficiency. ② Vitamin E (tocopherol): given in combination to suppress lipid peroxidation. ③ Alkalinization therapy: oral sodium bicarbonate (NaHCO₃) or sodium citrate to correct metabolic acidosis. ④ Transfusion: packed red blood cell transfusion to correct anemia during acute hemolytic episodes. ⑤ Folic acid supplementation is sometimes used as an adjunct. ⑥ Avoidance of drugs that induce oxidative stress (high-dose acetaminophen, flucloxacillin, aromatic antibiotics, etc.). Infection prevention (up-to-date vaccinations, early antibiotic treatment) is important for preventing hemolytic episodes.

Treatment of GGCS deficiency: Antioxidant treatment (vitamins C and E) and management of anemia. Rehabilitation for neuromuscular abnormalities.

Treatment of DPYS deficiency: There is no specific treatment for DPYS deficiency itself. The most important clinical measure is contraindication or marked dose reduction of 5-FU-based anticancer drugs (5-fluorouracil, capecitabine, tegafur). When DPYS deficiency is confirmed, the treating oncology team should be notified immediately to change the treatment plan. Selection of an alternative chemotherapy regimen is needed. If 5-FU toxicity has already occurred, intensive supportive care (transfusion, growth factors, mucosal care, nutritional support) is required.


11. Prognosis

Prognosis of the mild form of GSS deficiency: When anemia is managed with antioxidant treatment and correction of acidosis, normal growth and development are possible. Intelligence and neurological function are maintained in appropriately treated patients, and quality of life is relatively good. Because acute exacerbations (hemolytic episodes, worsening acidosis) occur in stressful situations such as infection, an emergency response plan is needed.

Prognosis of the severe form of GSS deficiency: Neurodevelopmental disorder due to recurrent metabolic acidosis and oxidative damage to the nervous system is the main prognostic determinant. With early diagnosis, antioxidant treatment and correction of acidosis, progression of neurological damage can be slowed, but damage that has already occurred is difficult to reverse. Cerebellar dysfunction and intellectual disability may remain.

Prognosis of DPYS deficiency: The prognosis is normal unless 5-FU-based chemotherapy is given. In patients who experienced 5-FU toxicity before diagnosis, morbidity due to toxic complications (severe mucosal damage, bone marrow suppression) can occur. With early diagnosis and avoidance of the anticancer drugs, survival and quality of life can be fully preserved.

Prognosis of beta-aminoisobutyric aciduria: Because it is a normal variant rather than a clinical disease, the prognosis is normal.


12. Prevention

GSS deficiency: Because it is autosomal recessive, carrier testing and genetic counseling of families of confirmed patients are important. Prenatal diagnosis (GSS gene analysis via CVS or amniocentesis) is possible. In confirmed patients, drugs that induce oxidative stress such as acetaminophen and flucloxacillin are avoided, and the focus is on infection prevention. Antioxidant supplementation with vitamins C and E is maintained continuously to minimize oxidative damage.

DPYS deficiency: It is ideal to test the pyrimidine degradation pathway genes (DPYD, DPYS) as part of pharmacogenomic screening before chemotherapy. Currently, DPYD genotyping is recommended before 5-FU treatment in guidelines of several countries, and DPYS testing is also gradually being introduced into clinical practice. In patients with confirmed DPYS deficiency, strict adherence to contraindication or marked dose reduction of 5-FU-based anticancer drugs is the key life-saving preventive measure.

In all rare amino acid metabolic disorders, actively offering genetic counseling, family testing and the opportunity for prenatal diagnosis is the foundation of primary prevention.


13. References

  1. Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis. 2007;2:16. DOI: 10.1186/1750-1172-2-16. PMID: 17411441.

  2. Njalsson R, Norgren S, Larsson A, et al. Pathophysiology and outcome of patients with glutathione synthetase deficiency. J Inherit Metab Dis. 2005;28(6):983-993. DOI: 10.1007/s10545-005-0030-0. PMID: 16435188.

  3. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenomics J. 2002;2(3):171-175. DOI: 10.1038/sj.tpj.6500102. PMID: 12025932.

  4. Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983;52:711-760. DOI: 10.1146/annurev.bi.52.070183.003431. PMID: 6137189.

  5. van Kuilenburg ABP, Dobritzsch D, Meinsma R, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res. 2003;9(12):4363-4367. PMID: 14555511.

  6. Jellum E, Kluge T, Borresen HC, et al. Pyroglutamic aciduria — a new inborn error of metabolism. Scand J Clin Lab Invest. 1970;26(4):327-335. DOI: 10.3109/00365517009072403. PMID: 4327720.

  7. Boehlein SK, Schuster SM. Glutathione synthetase deficiency: diagnosis and treatment. Exp Opin Orphan Drugs. 2013;1(5):399-407. DOI: 10.1517/21678707.2013.781997.

  8. Magnusson G, Liedén G, Lindblad BS, et al. Diagnosis and treatment of glutathione synthetase deficiency. J Pediatr. 1993;122(6):967-970. DOI: 10.1016/S0022-3476(09)90028-X. PMID: 8501567.

  9. Duley JA, Christodoulou J, de Brouwer AP. The DPYD pharmacogene: what are the challenges? Expert Opin Drug Metab Toxicol. 2019;15(9):725-735. DOI: 10.1080/17425255.2019.1650714. PMID: 31375044.

  10. Ezgu F. Inborn errors of metabolism. Adv Clin Chem. 2016;73:195-250. DOI: 10.1016/bs.acc.2015.12.001. PMID: 26975973.